Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
Pacira BioSciences (NASDAQ:PCRX) has announced it will release its third quarter 2024 financial results after U.S. markets close on Wednesday, November 6, 2024. The company will host a conference call and webcast at 4:30 p.m. ET following the release. Participants interested in the Q&A session must pre-register to receive dial-in information. The event will be accessible through the 'Events' page on Pacira's investor website, with a replay available for approximately two weeks after the call.
Pacira BioSciences (NASDAQ:PCRX) ha annunciato che renderà pubblici i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura dei mercati statunitensi il mercoledì 6 novembre 2024. L'azienda ospiterà una conference call e una diretta streaming alle 16:30 ET subito dopo la divulgazione. I partecipanti interessati alla sessione di domande e risposte devono preregistrarsi per ricevere le informazioni per il collegamento. L'evento sarà accessibile tramite la pagina 'Eventi' sul sito degli investitori di Pacira, con una riproduzione disponibile per circa due settimane dopo la chiamata.
Pacira BioSciences (NASDAQ:PCRX) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre de los mercados en EE. UU. el miércoles 6 de noviembre de 2024. La empresa llevará a cabo una llamada de conferencia y una transmisión en vivo a las 4:30 p.m. ET tras la publicación. Los participantes interesados en la sesión de preguntas y respuestas deben registrarse previamente para recibir la información para marcar. El evento será accesible a través de la página de 'Eventos' en el sitio web de inversores de Pacira, con una repetición disponible durante aproximadamente dos semanas después de la llamada.
Pacira BioSciences (NASDAQ:PCRX)가 2024년 3분기 재무 결과를 2024년 11월 6일 수요일 미국 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 발표 후 오후 4:30 ET에 전화회의 및 웹캐스트를 진행할 예정입니다. Q&A 세션에 참여하려는 참가자는 전화 접속 정보를 받기 위해 사전 등록해야 합니다. 이 행사는 Pacira의 투자자 웹사이트의 '이벤트' 페이지를 통해 접근 가능하며, 통화 이후 약 2주 동안 다시 들을 수 있습니다.
Pacira BioSciences (NASDAQ:PCRX) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la clôture des marchés américains le mercredi 6 novembre 2024. L'entreprise organisera une conférence téléphonique et un webcast à 16h30 ET après la publication. Les participants intéressés par la session de questions-réponses doivent s'inscrire à l'avance pour recevoir les informations d'appel. L'événement sera accessible via la page 'Événements' sur le site des investisseurs de Pacira, avec une rediffusion disponible pendant environ deux semaines après l'appel.
Pacira BioSciences (NASDAQ:PCRX) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach dem Schluss der US-Märkte am Mittwoch, den 6. November 2024 veröffentlichen wird. Das Unternehmen wird anschließend um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten. Teilnehmer, die an der Q&A-Session interessiert sind, müssen sich im Voraus registrieren, um die Einwahlinformationen zu erhalten. Die Veranstaltung ist über die 'Events'-Seite auf der Investorenseite von Pacira zugänglich, mit einer Wiederholung, die etwa zwei Wochen nach dem Anruf verfügbar sein wird.
- None.
- None.
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
FAQ
When will Pacira BioSciences (PCRX) release Q3 2024 earnings?
What time is Pacira BioSciences (PCRX) Q3 2024 earnings call?
How can I access Pacira BioSciences (PCRX) Q3 2024 earnings call?
How long will Pacira BioSciences (PCRX) Q3 2024 earnings call replay be available?
